Work

USP50 in the DNA damage response and the role of BRACA1 at stalled replication forks

Year: 2012
Type: dissertation
Abstract: The little-known deubiquitinating enzyme, USP50, has recently been observed to be important for G2/M cell cycle checkpoint activation and ubiquitin conjugate clearance at DNA damage repair.This project investigates the possible orthologs, predicted protein structure, protein domain active sites, conserved protein regions and cellular localisation of USP50.Also, this details the cloning strategy of creating wild-type and mutant USP50 inducible expression stable cell lines.Methodology utilised included; bioinformatics tools, protein structure modelling, immunofluorescene staining and cell culture.USP50 is a close homologue of USP8 but has a missing catalytic residue in the active site required for ubiquitin binding.Immunofluorescent data suggests USP50 is functional as overexpression leads to cellular defects and DNA damage.Due to such damage, inducible expression stable cell lines of wild-type and mutant USP50 are required to study USP50 function further.Evidence within the literature combined with our results suggest USP50 is active, despite the missing residue from its UCH active site.USP50 appears to be important for ubiquitin conjugate regulation at double-strand breaks. THE ROLE OF BRCA1 AT STALLED REPLICATION FORKSBRCA1 is a common inherited mutation in families with early onset breast and ovarian cancer.Cancers with homozygous mutations in BRCA1 are more resistant to chemotherapy due to abnormal DNA repair.Gemcitabine is a DNA replication inhibitor used to treat breast and ovarian cancer.How cancer mutations change the response of cells is poorly understood.Here, we investigate how BRCA1 mutations effect response to Gemcitabine using the cell line, HCC1937.BRCA1-proficient and -deficient cells were used to investigate the replication fork stalling, fork restart, 53BP1 and ɣH2AX foci, phospho-RPA levels, cell cycle accumulation and clonogenic survival after Gemcitabine treatment.Techniques utilised included DNA fibre analysis, immunofluorescent staining, FACS, Western blot and clonogenic survival assays.BRCA1-deficient cells display increased fork stalling and earlier induction of phospho-RPA, 53BP1 and ɣH2AX.BRCA1 status effects the accumulation of cells in S phase after Gemcitabine treatment.BRCA1-deficient cells show decreased survival to <10µM Gemcitabine treatment.We report that BRCA1 protects slowed and stalled forks, and prevents forks collapsing into double-strand breaks.BRCA1 status affects the sensitivity of cells to Gemcitabine treatment.
Language: English
Open Access status: green
OpenAlex ID: W128391410
Cites: 222
Cited by:
Related to: 10